Neuroprotective effects of Methylene Blue in Mild Traumatic Brain Injury

Methylene blue (MB) has energy-enhancing and antioxidant properties. MB treatment has been shown to reduce neurobehavioral impairment in Parkinson's disease and in Alzheimers disease in animals. This study investigated the novel neuroprotective effect of MB on mild traumatic brain injury (TBI) as measured by lesion volume, histology, and functional outcome. We found that MB treatment minimized lesion volume and functional deficits compared to vehicle-treated animals. Immunohistological staining for neuronal degeneration corroborated MRI lesion volume and behavioral data. MB has an excellent safety profile and is clinically approved for other indications. MB clinical trials on TBI can thus be readily explored.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.